Related Experiment Video
Updated: Aug 17, 2026

Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus (MRSA)
Published on: February 9, 2011
Influence of methicillin-resistant Staphylococcus aureus carrier status in liver transplant recipients
G Woeste1, C Zapletal, C Wullstein
1Department of Surgery, Johann Wolfgang Goethe-University Frankfurt, Frankfurt am Main, Germany. guido.woeste@kgu.de
Abstract:
The prevalence of methicillin-resistant Staphylococus aureus (MRSA) has increased worldwide and MRSA has emerged as an important cause of sepsis in cirrhotic patients and liver transplant recipients. In this retrospective study, the prevalence of MRSA colonization and its influence on infections following orthotopic liver transplantation (OLT) was investigated. From August, 2002 until November, 2004, 66 primary cadaver OLT were performed for adult recipients. Antibody induction used Daclizumab (n = 49) or ATG (n = 14). Maintenance immunosuppression consisted of tacrolimus and steroids, with 30 patients receiving mycophenolate mofetil and 4, rapamune. For perioperative anti-infectious prophylaxis cefotaxime, metronidazole, and tobramycin were administered for 48 hours. The preoperatively performed routine swabs revealed MRSA colonization in 12 of 66 (18.2%) patients. The stage of cirrhosis was equivalent for MRSA(-) patients according to Child score. The mean MELD score was significantly higher for MRSA(+) patients (24.3 versus 18.7, P = .036). More MRSA(+) patients were hospitalized at the time of transplantation (14/54 versus 8/12, P = .018). The incidence of posttransplant infections was not significantly different among the two groups. Within the first year 7 of 66 (10.6%) patients died: 3 of 12 (25%) MRSA(+) and 4 of 54 (7.4%) MRSA(-). The 1-year survival was lower in the MRSA(+) group (74.1% versus 94.1%). In conclusion, this study did not show that an MRSA-positive carrier status implies an increased risk for septic complications following OLT. Mortality was increased for MRSA(+), but failed to show a significant difference. A significantly higher MELD score and pretransplant hospitalization for MRSA(+) patients may contribute to the higher mortality and reflect sicker patients.
Insights
Methicillin-resistant Staphylococcus aureus (MRSA) colonization did not increase post-liver transplant infections. However, MRSA carriers had higher mortality rates, likely due to sicker patients pre-transplant.
Area of Science:
- Infectious Diseases
- Transplantation Immunology
- Hepatology
Background:
- Methicillin-resistant Staphylococcus aureus (MRSA) is a growing global health concern.
- MRSA is a significant cause of sepsis in patients with cirrhosis and liver transplant recipients.
- Understanding MRSA colonization's impact post-orthotopic liver transplantation (OLT) is crucial.
Purpose of the Study:
- To investigate the prevalence of MRSA colonization in OLT recipients.
- To determine if MRSA colonization influences post-OLT infections and survival.
Main Methods:
- Retrospective study of 66 adult OLT recipients (2002-2004).
- Preoperative screening for MRSA colonization.
- Analysis of post-transplant infections, mortality, and survival rates.
- Comparison between MRSA-positive and MRSA-negative groups.
Main Results:
- 18.2% of patients were colonized with MRSA pre-transplant.
- MRSA-positive patients had higher MELD scores and pre-transplant hospitalization rates.
- No significant difference in post-transplant infection incidence between groups.
- 1-year survival was lower in MRSA-positive patients (74.1% vs. 94.1%).
Conclusions:
- MRSA colonization did not correlate with increased septic complications post-OLT.
- Increased mortality in MRSA-positive patients may be linked to pre-existing conditions (higher MELD, hospitalization).
- Further research is needed to clarify the precise impact of MRSA carriage on OLT outcomes.
Related Concept Videos
Clinical Significance of Antibiotic Resistance
Staphylococcal Skin Infections
Mechanism of Antibiotic Resistance in MRSA
Kidney Transplant I: Introduction
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test